Roche and Nurix Sign $2.3 Billion Deal for Promising Blood Cancer Drug
Key Details of the Roche-Nurix Collaboration
Overview of the Agreement
ZURICH, June 8 (Reuters) - Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Focus on Bexobrutideg for Blood Cancer
• The deal focuses on blood cancer drug bexobrutideg, which degrades targeted proteins and is planned to enter a phase III clinical trial initiation for chronic lymphocytic leukaemia (CLL) in the summer
Financial Terms and Milestones
• Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones
Expert Commentary
• "We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases," Levi Garraway, Roche chief medical officer and head of global product development said
Deal Timeline and Structure
• The deal is expected to close in the third quarter of 2026
• Development costs for the drug will be covered 60% by Roche and 40% by Nurix
Commercialization and Profit Sharing
• The companies will co-commercialise the drug in the United States, where they will split the profits and losses equally, while Roche will commercialise outside of the U.S., paying Nurix royalties
(Reporting by Marleen Kaesebier and Oliver Hirt, Editing by Friederike Heine)
